L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors

International Journal of Cancer

Volumn 119, Issue 3, 2006, Pages 484-492

  Nawashiro, Hiroshi ^a   Otani, Naoki ^a   Shinomiya, Nariyoshi ^a   Fukui, Shinji ^a   Ooigawa, Hidetoshi ^a   Shima, Katsuji ^a   Matsuo, Hirotaka ^a   Kanai, Yoshikatsu ^b   Endou, Hitoshi ^b  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

BCH; Glioma; L type amino acid transporter (LAT1)

Indexed keywords

2 AMINOBICYCLO[2.2.1]HEPTANE 2 CARBOXYLIC ACID; 4F2HC ANTIGEN; AMINO ACID TRANSPORTER; CARBOXYLIC ACID DERIVATIVE; CD98 ANTIGEN; MEMBRANE ANTIGEN; ONCOFETAL ANTIGEN; PROTEIN INHIBITOR; TA1 ANTIGEN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; AMINO ACID TRANSPORT; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; ASTROCYTE; ASTROCYTIC TUMOR; BRAIN TUMOR; CANCER INHIBITION; CANCER SURVIVAL; CELL STRAIN; CELL STRAIN C6; CELL SURVIVAL; CHILD; CONTROLLED STUDY; DOSE RESPONSE; DRUG TARGETING; FEMALE; FETUS (ANATOMY); GENE EXPRESSION; GLIOBLASTOMA; GLIOMA; GLIOMA CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INFANT; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RAT; REGRESSION ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINO ACIDS, CYCLIC; ANIMALS; ANTIGENS, CD98 HEAVY CHAIN; ASTROCYTOMA; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CHILD; FEMALE; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT, NEWBORN; LARGE NEUTRAL AMINO ACID-TRANSPORTER 1; MALE; MIDDLE AGED; NEOPLASMS, EXPERIMENTAL; RATS; RATS, WISTAR; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 33646540633     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21866     Document Type: Article

References (23)

1. Shrieve DC, Alexander E, III, Black PM, Wen PY, Fine HA, Kooy HM, Loeffler JS. Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J Neurosurg 1999;90:72-7.
2. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994;367:576-9.
3. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 1998;273:23629-32.
4. Mastroberardino L, Spindler B, Pfeiffer R, Skelly PJ, Loffing J, Shoemaker CB, Verrey F. Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family. Nature 1998;395:288-91.
5. Gaugitsch HW, Prieschl EE, Kalthoff F, Huber NE, Baumruker T. A novel transiently expressed, integral membrane protein linked to cell activation. Molecular cloning via the rapid degradation signal AUUUA. J Biol Chem 1992;267:11267-73.
6. Sang J, Lim YP, Panzica M, Finch P, Thompson NL. TA1, a highly conserved oncofetal complementary DNA from rat hepatoma, encodes an integral membrane protein associated with liver development, carcinogenesis, and cell activation. Cancer Res 1995;55:1152-9.
7. Bruce JN, Falavigna A, Johnson JP, Hall JS, Birch BD, Yoon JT, Wu EX, Fine RL, Parsa AT. Intracerebral clysis in a rat glioma model. Neurosurgery 2000;46:683-91.
8. Kleihues P, Cavenee WK. Pathology and genetics of tumours of the nervous system. Lyon, France: IARC, 2000. p 6.
9. Chairoungdua A, Segawa H, Kim JY, Miyamoto K, Haga H, Fukui Y, Mizoguchi K, Ito H, Takeda E, Endou H, Kanai Y. Identification of an amino acid transporter associated with the cystinuria-related type II membrane glycoprotein. J Biol Chem 1999;274:28845-8.
10. Mannion BA, Kolesnikova TV, Lin SH, Wang S, Thompson NL, Hemler ME. The light chain of CD98 is identified as E16/TA1 protein. J Biol Chem 1998;273:33127-9.
11. Spindler B, Mastroberardino L, Custer M, Verrey F. Characterization of early aldosterone-induced RNAs identified in A6 kidney epithelia. Pflugers Arch 1997;434:323-31.
12. Wolf DA, Wang S, Panzia MA, Bassily NH, Thompson NL. Expression of a highly conserved oncofetal gene, TA1/E16, in human colon carcinoma and other primary cancers: homology to Schistosoma mansoni amino acid permease and Caenorhabditis elegans gene products. Cancer Res 1996;56:5012-22.
13. Shishido T, Uno S, Kamohara M, Tsuneoka-Suzuki T, Hashimoto Y, Enomoto T, Masuko T. Transformation of BALB3T3 cells caused by over-expression of rat CD98 heavy chain (HC) requires its association with light chain: mis-sense mutation in a cysteine residue of CD98HC eliminates its transforming activity. Int J Cancer 2000;87:311-316.
14. Nakamura E, Sato M, Yang H, Miyagawa F, Harasaki M, Tomita K, Matsuoka S, Noma A, Iwai K, Minato N. 4F2 (CD98) heavy chain is associated covalently with an amino acid transporter and controls intracellular trafficking and membrane topology of 4F2 heterodimer. J Biol Chem 1999;274:3009-3016.
15. Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T, Cha SH, Matsuo H, Fukushima J, Fukasawa Y, Tani Y, Taketani Y, et al. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta 2001;1514:291-302.
16. Campbell WA, Sah DE, Medina MM, Albina JE, Coleman WB, Thompson NL. TA1/LAT-1/CD98 light chain and system L activity, but not 4F2/CD98 heavy chain, respond to arginine availability in rat hepatic cells. Loss of response in tumor cells. J Biol Chem 2000;275:5347-54.
17. Samnick S, Bader JB, Hellwig D, Moringlane JR, Alexander C, Romeike BF, Feiden W, Kirsch CM. Clinical value of iodine-123-α-methyl-L-tyrosine single-photon emission tomography in the differential diagnosis of recurrent brain tumor in patients pretreated for glioma at follow-up. J Clin Oncol 2002;20:396-404.
18. Kuwert T, Probst-Cousin S, Woesler B, Morgenroth C, Lerch H, Matheja P, Palkovic S, Schafers M, Wassmann H, Gullotta F, Schober O. Iodine-123- methyltyrosine in gliomas: correlation with cellular density and proliferative activity. J Nucl Med 1997;38:1551-5.
19. Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del Fiore G, Luxen A, Reznik M. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998;39:778-85.
20. Langen KJ, Bonnie R, Muhlensiepen H, Jansen P, Broer S, Holschbach M, Coenen HH. 3-[123I]iodo-α-methyl-L-tyrosine transport and 4F2 antigen expression in human glioma cells. Nucl Med Biol 2001;28:5-11.
21. Shikano N, Kanai Y, Kawai K, Ishikawa N, Endou H. Characterization of 3-[125I]iodo-α-methyl-L-tyrosine transport via human L-type amino acid transporter 1. Nucl Med Biol 2003;30:31-7.
22. Langen KJ, Roosen N, Coenen HH, Kuikka JT, Kuwert T, Herzog H, Stocklin G, Feinendegen LE. Brain and brain tumor uptake of L-3-[123I]iodo-methyl tyrosine: competition with natural L-amino acids. J Nucl Med 1991;32:1225-8.
23. Storey BT, Fugere C, Lesieur-Brooks A, Vaslet C, Thompson NL. Adenoviral modulation of the tumor-associated system L amino acid transporter, LAT1, alters amino acid transport, cell growth and 4F2/CD98 expression with cell-type specific effects in cultured hepatic cells. Int J Cancer 2005;117:387-97.